金融界2025年5月12日消息，中欧医疗创新股票A(006228) 最新净值1.1755元，下跌3.18%。该基金近1个 月收益率2.39%，同类排名515|702；近3个月收益率12.51%，同类排名26|701；今年来收益率13.05%， 同类排名48|696。 来源：金融界 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(20 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has seen a decline in its net value and varying returns over different time frames [1] - As of May 12, 2025, the latest net value of the fund is 1.4849 yuan, reflecting a decrease of 1.90% [1] - The fund's performance over the past month shows a return of 0.75%, ranking 1780 out of 1948 in its category; over the past three months, it has a return of -0.05%, ranking 956 out of 1931; and since the beginning of the year, it has a return of -1.56%, ranking 1595 out of 1919 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan, managed by fund manager Ge Lan [1]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

广发证券联席 首席金工分析师 陈原文 SAC: S0260517080003 chenyuanwen@gf.com.cn 广发证券首席金工分析师 安宁宁 SAC: S0260512020003 anningning@gf.com.cn 广发证券资深金工分析师 张钰东 SAC: S0260522070006 zhangyudong@gf.com.cn 广发金工安宁宁陈原文团队 摘要 指数定期调整预测。 中证指数有限公司及深圳证券信息有限公司在每年的6月及12月会根据指数编制方案对主要的宽 基核心指数成分股进行定期的调整。 上证50指数调整预测。 根据上证50指数编制规则，2025年6月将会有中国海油、上汽集团等5只个股被调入上证50指 数，而海天味业等5只个股被调出上证50指数。 深证100指数调整预测。 根据深证100指数编制规则，2025年6月将会有中航成飞、光启技术等4只个股被调入深证100 指数，而TCL中环、康龙化成等4只个股被调出深证100指数。 科创50指数调整预测。 根据科创50指数编制规则，2025年6月将会有百济神州、华虹公司等4只个股被调入科创50指 数，而华大智造、天岳先进等4只个股被调 ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, suggesting a potential for growth in 2025 due to favorable macroeconomic factors and the recovery of public fund allocations to the sector [11]. Core Insights - The pharmaceutical sector is currently undervalued, with public fund allocations at a low point, but is expected to recover, driven by large-scale products and innovations [11]. - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and international pipelines [11]. - In the medical device sector, there is a notable recovery in bidding volumes, particularly for imaging equipment, and a push for home medical devices supported by government subsidies [11]. - The report identifies a significant growth opportunity in the CXO and life sciences services sectors, with expectations of a rebound in domestic financing and a trend towards consolidation [11]. - The traditional Chinese medicine sector is expected to see growth driven by unique essential medicines and state-owned enterprise reforms [11]. Summary by Sections Market Review - The medical device index increased by 0.98%, underperforming the CSI 300 index by 1.03 percentage points, ranking 26th among 30 sectors [8]. - The top ten stocks by growth included JinHao Medical and ChangShan Pharmaceutical, while the bottom ten included ST HuLuWa and YongAn Pharmaceutical [8]. Medical Device Updates - The report notes a significant increase in medical device bidding volumes, with a year-on-year growth of 67.49% in Q1 2025, indicating a strong recovery [20]. - Imaging devices, particularly ultrasound, CT, and DR, are highlighted as the most sought-after categories in procurement [25]. - The report anticipates a surge in procurement activities in county-level medical communities, driven by government support policies [29]. Innovative Drugs - The report emphasizes the growth potential in the innovative drug sector, particularly for companies like BeiGene and Innovent Biologics, which are expected to benefit from their differentiated product pipelines [11]. - The focus on autoimmune diseases is noted as a new growth curve for companies like Nuo Cheng Jian Hua, with significant market potential [37]. Medical Services - The report suggests that the medical service sector will benefit from anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private medical institutions [11]. Blood Products - The blood products sector is expected to grow due to relaxed approval processes for plasma stations and increased demand post-pandemic, with companies like TianTan Biological and BoYa Biological highlighted as key players [11].

Core Viewpoint - Bidder Pharmaceutical, established in 2007, provides specialized and efficient drug molecular building blocks and scientific reagent products and services for new drug research and development. The company focuses on a "more, faster, better, cheaper" core advantage and employs a model of "horizontal expansion of product variety + vertical deepening of advantageous product lines" to serve the new drug development industry chain [2][3]. Industry Overview - Domestic market demand is recovering, with a pressing need for domestic alternatives. Research funding continues to grow, and policies such as U.S. tariffs are pushing downstream sectors to seek domestic alternatives, creating market expansion opportunities for local manufacturers [2][36]. - Overseas demand is rebounding, with a need for breakthroughs in the market. Since the second half of 2023, investment amounts in U.S. biopharmaceuticals have shown improvement, indicating increased demand from overseas pharmaceutical companies and CROs [2][36]. Company Performance - Bidder Pharmaceutical has expanded its inventory to 130,000 types of stock products, offering over 500,000 novel and multifunctional drug molecular building blocks to meet downstream demands [2][82]. - The company has increased its R&D investment, with some products reaching international advanced levels while maintaining price advantages. R&D expenses grew from 13.83 million yuan in 2018 to 59.05 million yuan in 2024, with a CAGR of 27.37% [2][86]. - Bidder's overseas revenue for 2024 is projected to be 616 million yuan, with a gross margin of 50.40%, significantly higher than domestic margins. The company has achieved a CAGR of 43.52% in revenue from 2018 to 2024 [2][82]. - The company is transitioning towards high-quality development, with revenue expected to return to high growth and significant profit elasticity in the future [2][82]. Product Offering - The main products include drug molecular building blocks, which can be subdivided into heterocyclic compounds, aromatic compounds, and aliphatic compounds, as well as scientific reagents essential for new drug development [2][6][7]. - The company currently has 128,000 types of stock products, capable of providing over 500,000 novel and multifunctional drug molecular building blocks to meet the high-tech, multi-category, small dosage, and frequent demand from downstream clients [2][6]. Competitive Landscape - The global market for drug molecular building blocks is estimated to reach $21.8 billion in 2024, primarily dominated by foreign companies. Domestic companies, while competitive in niche areas, still lag significantly in overall scale and market share compared to international giants [2][77][80]. - Bidder Pharmaceutical's pricing for some common reagents is only 1/5 to 1/10 of that of international leader Sigma-Aldrich, with purity indicators meeting international advanced levels, positioning the company favorably in the context of accelerating domestic substitution [2][90].

Market Overview - The Hong Kong stock market saw all three major indices close higher on May 8, with the Hang Seng Index rising by 0.37%, the Hang Seng China Enterprises Index increasing by 0.7%, and the Hang Seng Tech Index up by 0.56% [1] Sector Performance - The pharmaceutical sector showed signs of recovery, with notable gains in companies such as Zhaoyan New Drug (up 5.63%), WuXi Biologics (up 3.92%), and Kanglong Chemical (up 1.62%) [1] - The automotive sector was active, highlighted by Li Auto-W, which rose by 4.96% ahead of the launch of its new L series models [1] - Technology-related stocks, including mobile gaming and cloud computing, mostly experienced gains, with Boyaa Interactive rising by 10.38% and Tencent Holdings increasing by 1.67% [2] Consumer Sector - The consumer sector saw collective movements in cosmetics, tobacco, and home appliances, with China Tobacco Hong Kong rising by 8.27% and JS Global Life increasing by 3.39% [2] - Conversely, retail and luxury goods stocks faced declines, with Samsonite dropping by 3.64% and Prada falling by 3.82% [2] Notable Stock Movements - Geely Automobile rose by 4.41% as it announced plans to privatize its brand Zeekr at a premium of 13.6% [4] - Youju Holdings surged by 150% following a change in controlling interest and a buyout offer at a 41.7% discount [5] - Shanghai Auntie saw a significant first-day listing increase of 40.03%, bringing its total market capitalization to HKD 16.225 billion [6]

Market Overview - The Hong Kong stock market showed a general upward trend, with the Hang Seng Index rising by 0.37%, the Hang Seng China Enterprises Index increasing by 0.7%, and the Hang Seng Tech Index up by 0.56%, marking a six-day consecutive rise for the Hang Seng Index [1][2]. Sector Performance - Major technology stocks maintained an upward trend, with Meituan and Tencent both rising nearly 2%, Xiaomi up 1.4%, while Baidu fell nearly 3% and NetEase showed a decline [2]. - Defense stocks surged due to escalating tensions in the India-Pakistan conflict, with AVIC Industry and China Shipbuilding Defense both rising over 6% [4][5]. - Bitcoin briefly surpassed $99,000, leading to a significant rise in cryptocurrency-related stocks, with New Fire Technology Holdings soaring nearly 20% [2]. - The automotive sector saw strong performance, with companies like Geely, Li Auto, and Great Wall Motors all rising over 4% [8]. - Gaming stocks also performed well, with Huicai Holdings increasing over 13% and Sands China up over 1% [9]. - Consumer electronics and home appliance stocks were active, with JS Global Life rising over 3% and TCL Electronics up over 2% [10]. - Agricultural stocks increased, with China Heartlink Fertilizer and First Tractor Company both rising over 3% [11]. - Power sector stocks strengthened, with Harbin Electric rising over 4% [12]. - Steel stocks experienced significant declines, with Find Steel Group dropping over 12% [13]. Individual Stock Highlights - AVIC Industry closed at HKD 4.09, up 6.23%, while China Shipbuilding Defense closed at HKD 10.92, up 6.02% [6]. - Pharmaceutical outsourcing stocks were active, with Zhaoyan New Drug rising over 5% [7]. - The debut of "Hushang Aunt" saw a significant increase of 40%, closing at HKD 158.4 per share, with a total market capitalization of HKD 16.225 billion [16]. - Southbound funds recorded a net sell of HKD 2.385 billion, with the Shanghai-Hong Kong Stock Connect seeing a net sell of HKD 1.097 billion [18]. Future Outlook - Zhejiang International expresses caution regarding the short-term fundamentals and capital flows in the Hong Kong market, while maintaining a cautiously optimistic view on the medium-term outlook [20]. - The company recommends focusing on sectors that are relatively prosperous and benefit from policy support, such as automotive, consumer, electronics, and technology, as well as low-valuation state-owned enterprises [20].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 7, 2025, the latest net value of the fund is 1.5753 yuan, reflecting a decrease of 1.28%. The fund's return over the past month is -2.61%, ranking 4118 out of 4649 in its category. Over the past three months, the return is 4.24%, ranking 1179 out of 4597, and since the beginning of the year, the return is 1.73%, ranking 2415 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University in the United States. She has held various research and fund management positions before becoming the manager of the China Europe Medical Health Mixed Fund [2]